Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$372.5M
20M shares
52-week range
$11.09 – $21.01
74% from low
Sector
SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN
Exchange
NASDAQ
CS
P/S (TTM)
4.5
EV / FCF (TTM)
12.9
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
www.simulations-plus.comNo one on the platform currently holds SLP.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 181,500 | $2.1M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2024-07-29 | $0.0600 | 2024-08-05 |
| 2024-04-26 | $0.0600 | 2024-05-06 |
| 2024-01-26 | $0.0600 | 2024-02-05 |
| 2023-10-27 | $0.0600 | 2023-11-06 |
| Execution date | Ratio |
|---|---|
| 2007-10-02 | 2-for-1 |
| 2006-08-14 | 2-for-1 |
No one on the platform has traded SLP yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 13.1% | 13.7% | ||||
| Profit Margin % | -81.7% | -1.3% | 12.0% | |||
| Free Cash Flow Margin % | 22.0% | 25.4% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +6.5% on the P/E track.
At today's price, your expected annual return is +11.4% on the P/E track.
At today's price, your expected annual return is +15.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $86M | +5.2% | $0.91 | $0.90–$0.91 | 20.3× | 3 |
| 2028 | $93M | +7.4% | $1.06 | $1.05–$1.06 | 17.4× | 1 |
| 2029 | $103M | +11.7% | $1.28 | $1.27–$1.29 | 14.4× | 1 |
| 2030 | $117M | +13.2% | $1.56 | $1.55–$1.57 | 11.8× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-09 | $0.23 | $0.30 | +29.0% |
| 2026-04-09 | $0.27 | $0.35 | +29.6% |
| 2026-01-08 | $0.18 | $0.13 | -27.8% |
| 2025-12-01 | $0.10 | $0.10 | +0.0% |
| 2025-07-14 | $0.26 | $0.45 | +73.1% |
| 2025-04-03 | $0.25 | $0.31 | +24.0% |
| 2025-01-07 | $0.18 | $0.17 | -5.6% |
| 2024-10-23 | $0.07 |
| $0.06 |
| -9.1% |
| $162M |
| — |
| DHDefinitive Healthcare Corp. | $1.00 | -1.96% | $106M | — |
| KRROKorro Bio, Inc. | $14.07 | +1.37% | $140M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SLP here comes my vote - we are being sold for too cheap so no
View on StockTwits ↗
$DAL $WDFC and $SLP finish the week of July 6, 2026 https://www.earningswhispers.com/calendar
View on StockTwits ↗
$SLP seeing a big move up. This shows the importance of focusing on the right chart and timing regardless of overall market conditions. No FOMO, no FUD, looking forward to a great month ahead.
View on StockTwits ↗
$SLP Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit Tuesday, 23rd June at 9:15 am New capabilities connect AI agents, scientific literature, and validated computational engines to accelerate model-informed drug development Simulations Plus, Inc. (NASDAQ: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that helps advance biopharma innovation, today announced it is building the agentic layer of Composer, its AI-native platform for model-informed drug development, using the NVIDIA BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, extending their work in GPU-accelerated simulation and AI-assisted modeling workflows into agentic drug development. Together, the companies are combining AI reasoning, scientific literature, validated computational engines, and scalable compute within a scientific workflow. The announcement coincides with NVIDIA’s introduction of the BioNeMo Agent Toolkit at the BIO International Convention. The integration is initially focused on two areas:
View on StockTwits ↗
$SLP announced a merger agreement to be acquired, offering $18.50 cash per share.
View on StockTwits ↗
$SLP Why Shares in Simulation Plus Soared Today https://marketwirenews.com/stock/slp/news/why-shares-in-simulation-plus-soared-today-8319582494205761.html?utm_source=stocktwits
View on StockTwits ↗
Leerink thinks $CERT stock is way too cheap. It's still very profitable with strong long-term growth ahead. Today's purchase of rival $SLP at a ~90% premium to Certara's value highlights how undervalued it is.
View on StockTwits ↗
@No_Face_character @Jblack500 @WAJeff @cynicaloptimist @IsabellaDC @BustaCapital They are still $BEG ging +10.48 $WYFI $SLP $INOD
View on StockTwits ↗$SLP has agreed to be acquired by Altaris for approximately $375 million. Stockholders will receive $18.50 per share in cash. The deal is expected to close in Q4 2026. https://notreload.xyz/xy/altaris-to-acquire-simulations-plus-for-375m/
View on StockTwits ↗$SLP communicates execution of a merger agreement, making the company a wholly owned subsidiary of Altaris.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.